Gaze Bio Initiates Commercialization of Cancer-Related Epigenome Analysis Panel
Sep 26, 2024
Gaze Biomaterials (CEO Park Hee-kyung), a company specializing in dielectric-based molecular diagnosis, recently announced that it is actively developing innovative cancer diagnosis technology using a dielectric methylation panel (MPP Panel).
Dielectric methylation refers to a chemical reaction that occurs in the body. In other words, it refers to the reaction that occurs when a small molecule called methyl group attaches to the DNA.
DNA methylation is deeply associated with cancer in that it regulates gene expression. Abnormal methylation types in cancer cells are considered to be overall hypomethylation and hypermethylation of specific sites. In other words, the balance of the system that manages genome expression collapses, causing cancer.
Accordingly, cancer research using dielectric methylation has been actively conducted in recent years. In particular, in the case of pancreatic cancer and lung cancer, the importance of early diagnosis is growing as it is an intractable cancer that is difficult to detect early.
The research on the use of MPP panels by Sisang Bio is characterized by presenting new answers to solve these challenges.
In fact, MPP panels play an important role in early cancer diagnosis by helping to distinguish methylation differences between cancer cells and normal cells.
Shi's Bio did not use bisulfite differential reagents based on the original technology 'Epi-TOP methylation detection method', increasing judgment reproducibility and speed. Bisulfite pretreatment has problems such as DNA damage, decreased accuracy and reproducibility, and increased false-positive rates.
On the other hand, Epi-sPNA, developed by Siksa Bio, solves this problem by utilizing a functional PNA (artificial DNA) oligomer that selectively binds to methylated DNA.
Based on the technology, Si-seon Bio discovered a lung cancer-specific methylation biomarker and published the results of its lung cancer diagnosis in an overseas journal with Konkuk University Hospital's Lung Cancer Center. The paper was published in the famous journal 『Cancers" using the BALF exosome DNA methylation profile" to distinguish between lung cancer and lung disease using the BALF exosome DNA methylation profile".
In addition, through a joint study with the Department of Hematology and Oncology at Chungbuk National University Hospital, 'New Diagnostic Biomarker for Pancreatic Cancer: Novel Diagnostic Biomarkers for Pancreatic Cancer Evaluation (Nobel Diagnostic Biomarkers for Pancreatic Cancer: Assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA)' was published in the academic journal 'Frontiers in Oncology'.
Based on the methylation analysis technology of cancer-related genes, Si-seon Bio is actively developing various early cancer diagnosis products such as lung cancer. In particular, in order to verify the value of MPP, Siyeon Bio is conducting joint research with large medical institutions as well as its own research and development.
In addition, it plans to further increase the accuracy and reliability of the analysis panel through additional joint research underway with leading university hospitals in Korea.
"Early diagnosis through MPP Panel is expected to not only provide new hope for cancer patients but also contribute to the development of customized treatment approaches," said Park Hee-kyung, CEO of Si-seon Bio. "We are continuously conducting research and development for the commercialization and clinical application of cancer diagnosis technology through methylation panels and doing our best to provide better diagnosis and treatment to patients."," he said.
Dielectric methylation refers to a chemical reaction that occurs in the body. In other words, it refers to the reaction that occurs when a small molecule called methyl group attaches to the DNA.
DNA methylation is deeply associated with cancer in that it regulates gene expression. Abnormal methylation types in cancer cells are considered to be overall hypomethylation and hypermethylation of specific sites. In other words, the balance of the system that manages genome expression collapses, causing cancer.
Accordingly, cancer research using dielectric methylation has been actively conducted in recent years. In particular, in the case of pancreatic cancer and lung cancer, the importance of early diagnosis is growing as it is an intractable cancer that is difficult to detect early.
The research on the use of MPP panels by Sisang Bio is characterized by presenting new answers to solve these challenges.
In fact, MPP panels play an important role in early cancer diagnosis by helping to distinguish methylation differences between cancer cells and normal cells.
Shi's Bio did not use bisulfite differential reagents based on the original technology 'Epi-TOP methylation detection method', increasing judgment reproducibility and speed. Bisulfite pretreatment has problems such as DNA damage, decreased accuracy and reproducibility, and increased false-positive rates.
On the other hand, Epi-sPNA, developed by Siksa Bio, solves this problem by utilizing a functional PNA (artificial DNA) oligomer that selectively binds to methylated DNA.
Based on the technology, Si-seon Bio discovered a lung cancer-specific methylation biomarker and published the results of its lung cancer diagnosis in an overseas journal with Konkuk University Hospital's Lung Cancer Center. The paper was published in the famous journal 『Cancers" using the BALF exosome DNA methylation profile" to distinguish between lung cancer and lung disease using the BALF exosome DNA methylation profile".
In addition, through a joint study with the Department of Hematology and Oncology at Chungbuk National University Hospital, 'New Diagnostic Biomarker for Pancreatic Cancer: Novel Diagnostic Biomarkers for Pancreatic Cancer Evaluation (Nobel Diagnostic Biomarkers for Pancreatic Cancer: Assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA)' was published in the academic journal 'Frontiers in Oncology'.
Based on the methylation analysis technology of cancer-related genes, Si-seon Bio is actively developing various early cancer diagnosis products such as lung cancer. In particular, in order to verify the value of MPP, Siyeon Bio is conducting joint research with large medical institutions as well as its own research and development.
In addition, it plans to further increase the accuracy and reliability of the analysis panel through additional joint research underway with leading university hospitals in Korea.
"Early diagnosis through MPP Panel is expected to not only provide new hope for cancer patients but also contribute to the development of customized treatment approaches," said Park Hee-kyung, CEO of Si-seon Bio. "We are continuously conducting research and development for the commercialization and clinical application of cancer diagnosis technology through methylation panels and doing our best to provide better diagnosis and treatment to patients."," he said.
|
bellho@sportschosun.com
